Diagnostic Radioisotopes Market Report 2025

This Diagnostic Radioisotopes market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The diagnostic radioisotopes market size has grown rapidly in recent years. It will grow from $5.54 billion in 2024 to $6.1 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to the discovery of radioactivity, the introduction of technetium-99m, clinical applications and research, cold war era and nuclear research, and emergence of positron emission tomography.

The diagnostic radioisotopes market size is expected to see strong growth in the next few years. It will grow to $8.83 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to emerging radioisotope production methods, expanded clinical applications, patient-centered care and safety, point-of-care imaging and environmental sustainability and green chemistry. Major trends in the forecast period include hybrid imaging techniques, theranostics, molecular imaging techniques, the use of cyclotrons or generators, and safety and radiation protection.

The growing burden of cancer is expected to drive the expansion of the diagnostic radioisotopes market. Cancer is a disease characterized by the uncontrolled division of abnormal cells that damage surrounding tissue. The increasing prevalence of cancer is attributed to various factors, including lifestyle choices such as smoking, obesity, lack of physical activity, exposure to carcinogens, genetic factors, and environmental influences. Radioisotopes play a crucial role in cancer management by providing accurate diagnosis, enabling targeted treatments, and facilitating effective monitoring of cancer progression or response to therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency focused on cancer research and training, projected that by 2040, the global number of new cancer cases per year will reach 29.9 million, with 15.3 million cancer-related deaths. As a result, the rising burden of cancer is driving the growth of the diagnostic radioisotopes market.

Key players in the diagnostic radioisotopes market are focused on advancing radiopharmaceutical technology to enhance diagnostic accuracy, improve patient outcomes, and expand the applications of nuclear medicine in healthcare. Advanced radiopharmaceutical technology involves the development of innovative compounds and techniques for precise imaging and targeted therapy in nuclear medicine. For example, Bracco Group, an Italy-based diagnostic imaging company, launched Blue Earth Therapeutics in March 2022, a subsidiary dedicated to advancing next-generation therapeutic radiopharmaceutical technology, initially targeting prostate cancer with plans for further expansion into other oncology areas.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS to strengthen its supply chain and manufacturing capabilities. This acquisition aims to leverage ARTMS' expertise in cyclotron-based isotope production to enhance market position and meet the growing demand for diagnostic and therapeutic isotopes. ARTMS, headquartered in Canada, specializes in radioisotope technology and is a leading provider of diagnostic radioisotopes.

Major companies operating in the diagnostic radioisotopes market are Cardinal Health Inc., Sumitomo Heavy Industries Ltd., BWX Technologies Inc., Lantheus Holdings, Curium Pharma, Clarity Pharmaceuticals, Bracco Diagnostic Inc., Ion Beam Applications S.A., Nordion Inc., Eckert & Ziegler AG, NorthStar Medical Radioisotopes LLC, NTP Radioisotopes SOC Ltd, Global Medical Solutions Ltd., Isotopia Molecular Imaging Ltd., Cyclopharm Limited, Trasis NV, Orano Med LLC, ARTMS Inc., Radiomedix Inc., Coqu RadioPharmaceuticals Corp., IsoTherapeutics Group LLC.

North America was the largest region in the diagnostic radioisotopes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diagnostic radioisotopes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diagnostic radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diagnostic radioisotopes are radioactive isotopes employed in nuclear medicine for diagnosing and monitoring diverse medical conditions. They rely on their radioactive decay characteristics to emit radiation, detected by specialized imaging tools, enabling healthcare providers to acquire detailed internal body structure images and evaluate their function.

The primary diagnostic radioisotopes include technetium-99m, thallium-201, gallium-67, iodine-123, fluorodeoxyglucose (FDG), rubidium-82, and others. Technetium-99m is extensively used in medical imaging due to its advantageous nuclear properties and wide accessibility. Imaging techniques include single photon emission computed tomography (SPECT), positron emission tomography (PET), and beta emitters, employed across various fields such as oncology and cardiology.

The diagnostic radioisotopes research report is one of a series of new reports that provides diagnostic radioisotopes market statistics, including the diagnostic radioisotopes industry's global market size, regional shares, competitors with a diagnostic radioisotopes market share, detailed diagnostic radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the diagnostic radioisotopes industry. This diagnostic radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The diagnostic radioisotopes market consists of revenues earned by entities by providing services such as radiopharmacy services, imaging services, radioisotope production and supply, diagnostic procedures, and theranostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The diagnostic radioisotopes market also includes sales of products including Indium-111, Xenon-133, Molybdenum-99, and Phosphorus-32. Values in this market are 'factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.